Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?
Juvenile cystinosis was diagnosed in a patient who presented with severe headache attacks and photophobia. Treatment with oral cysteamine and topical cysteamine eye drops was started. One-and-a-half years later, he developed unilateral gynecomastia and elevated prolactin and growth hormone levels. A pituitary macroprolactinoma was discovered and successfully treated with the dopamine agonist cabergoline. Increased serum growth hormone levels were attributed to enhanced growth hormone production by the prolactinoma and somatostatin inhibition by cysteamine. Although the occurrence of prolactinoma in this patient could be a simple coincidence, it might also be a rare yet unrecognised complication of cystinosis.
Besouw
Martine T P
MT
Department of Pediatric Nephrology, University Medical Centre St Radboud, Nijmegen, The Netherlands.
Levtchenko
Elena N
EN
Willemsen
Michèl A A P
MA
Noordam
Kees
K
D000284:Administration, Oral; D000287:Administration, Topical; D001827:Body Height / Q000187:drug effects; D000077465:Cabergoline; D002648:Child; D003543:Cysteamine / Q000627:therapeutic use; D003554:Cystinosis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D006261:Headache / Q000209:etiology; D019382:Human Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D015175:Prolactinoma / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D009883:Ophthalmic Solutions; D011837:Radiation-Protective Agents; D019382:Human Growth Hormone; D003543:Cysteamine; D000077465:Cabergoline